Mechanistically, SCMNP therapy significantly reduced the levels of p-Akt and p-ERK proteins in the mice tumor, indicating that the drug’s substantial suppressive effects on tumor development in vivo may be caused by angiogenic malfunction [54]. This evidence concerns the gene AKT1 and neoplasm.